1. The association between serum ferritin and bilirubin with glycemic control among patients with type 2 diabetes mellitus.
- Author
-
Al Argan R, Alkhafaji D, Al Elq A, Albaker W, Elamin Y, Alwaheed A, Zeeshan M, AlElq Z, Alkhalifa M, Al Mansour R, Alghamdi S, Al Ghamdi A, Ismaeel F, Almarzouq A, Zainuddin F, and AlSulaiman R
- Subjects
- Male, Humans, Female, Bilirubin therapeutic use, Glycemic Control, Cross-Sectional Studies, Hypoglycemic Agents therapeutic use, Ferritins therapeutic use, Blood Glucose, Diabetes Mellitus, Type 2
- Abstract
Previous evidence has shown an association between serum ferritin and bilirubin levels in the development of type 2 diabetes mellitus (T2DM) and glycemic control. However, the evidence is scarce in Saudi Arabia. In this study, we aimed to evaluate the association between serum ferritin and bilirubin levels with glycemic control in patients with T2DM. This was a cross-sectional study that involved 153 patients with T2DM recruited from outpatient diabetes clinics. Participants were categorized into two groups: well-controlled and uncontrolled T2DM, based on their glycemic status. We focused on comparing the iron profile and bilirubin levels between these two groups and examining the influence of antidiabetic medications on these parameters. A total of 153 patients with T2DM were included (58.2% women and 41.8% men). In both univariate and multivariate analyses, ferritin levels did not have a statistically significant association with glycemic control. However, patients with well-controlled T2DM had a significantly higher median level of total bilirubin and direct bilirubin than those with uncontrolled T2DM. Only direct bilirubin showed a statistically significant association with FBG less than 130 mg/dl and HbA1c level less than 7.0%. Ferritin level was not associated with glycemic control in patients with T2DM. On the other hand, direct bilirubin level was an independent predictor of better glycemic control. Monitoring direct bilirubin levels could aid in predicting glycemic control in T2DM and could be a potential target for developing antidiabetic medications., Competing Interests: The authors declare no conflict of interest., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF